Company Overview
| Stock Name | Hua Medicine-B |
|---|---|
| Stock Code | 02552 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 華領醫藥是一家中國藥物開發公司,目前致力於開發用於治療2型糖尿病的全球首創口服新藥Dorzagliatin或HMS5552。 |
| Listing Date | 2018-09-14 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市愛迪生路275號華領醫藥(郵編:201203) |
| Business Address (Hong Kong) | 香港灣仔軒尼詩道36號循道衛理大廈2202室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.huamedicine.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 8.28 / shares |
| Offer Price Range | To be extracted |
| Lot Size | 500 shares |
| Entry Threshold | To be extracted |
| Par Value | RMB 0.001 / shares |
| Offer Period | 2018-08-31 to 2018-09-05 |
| Global Offering Shares | 104,756,000 shares |
| HK Public Offer Shares (Initial) | 10,476,000 shares (10.0%) |
| Public Offer Lots (Initial) | 20,952lots (Pool A10,476lots,Pool B10,476lots) |
| International Placing Shares (Initial) | 94,280,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,051,913,300 shares |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 867,379,680 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 2.83B |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +244% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 9,235,798,774 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣280.7百萬元 |
| Period-End Cash Balance | 人民幣172.7百萬元 |
| Listing Expenses | ~HK$ 89,057,680 |
| Listing Expenses / Funds Raised | ~10.27% |
| Total Pre-IPO Investment | 210.5百萬美元 |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2016 | 2017 | 2018-03 |
|---|---|---|---|
| Other income and gains, net | 1,030 | 11,706 | 6,110 |
| Administrative expenses | -19,482 | -31,086 | -13,725 |
| Net finance costs | -4,562 | -2,958 | -4,500 |
| Profit before tax | -362,408 | -280,688 | -322,322 |
| Income tax expense | 0 | 0 | 0 |
| Profit for the year | -362,408 | -280,688 | -322,322 |
| Profit attributable to owners | -361,328 | -272,714 | -321,053 |
Balance Sheet
| Item | 2016 | 2017 | 2018-03 |
|---|---|---|---|
| Cash and cash equivalents | 192,901 | 172,733 | 836,064 |
| Total current assets | 224,541 | 232,288 | 906,533 |
| Total current liabilities | 25,281 | 42,997 | 49,295 |
| Total equity | -666,196 | -942,530 | -1,259,854 |
| Equity attributable to owners | -670,142 | -953,880 | -1,262,762 |
Cash Flow Statement
| Item | 2016 | 2017 | 2018-03 |
|---|---|---|---|
| Net cash from operating activities | -76,051 | -198,694 | -66,085 |
| Net cash from investing activities | -29,241 | 14,475 | -112 |
| Net cash from financing activities | 151,259 | 172,904 | 738,470 |
| Net increase in cash | 55,292 | -20,168 | 663,331 |
| Depreciation of PP&E | 361 | 637 | 241 |
| Purchase of PP&E | -647 | -2,419 | -418 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 8.28 |
|---|---|
| First Day Open | HK$ 8.28 |
| First Day Change | -55.80% |
| First Day Volume | 11815000.0 |
| First Day Turnover | 96901900.0 |
| Use of Proceeds | 1、約39%(或304.4百萬港元)將用于在未來兩年內完成Dorzagliatin進行III期試驗, 其中約35%分配至單藥治療試驗,而65%則分配至與二甲雙胍聯合療法試驗;
2、約9%(或70.3百萬港元)將用于在未來三年內涉及Dorzagliatin的進一步研發,將包括聯用試驗;
3、約27%(或210.8百萬港元)將用于在未來三年內在中國推出Dorzagliatin及商業 化,包括營銷、銷售及生產;
4、約11%(或85.9百萬港元)將用于在未來三年內進一步研究涉及Dorzagliatin的固 定劑量組合及個人化糖尿病以及mGLUR5的研究;
5、約4%(或31.2百萬港元)將用于在未來三年內開拓直接與糖尿病或我們認為重大醫 療需求而未被滿足的新治療領域有關的其他特許及合伙商機;
6、約10%(或78.1百萬港元)將用作我們的一般公司及營運資金用途。 |
Underwriting Syndicate
Joint Sponsors (2)
Overall Coordinators (3)
Joint Bookrunners (3)
Joint Lead Managers (4)
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 陳力 | — |
| Company Secretary | 鄭杏怡 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 主要股東包括ARCH Venture Fund VII, L.P.(約11.89%)、The Core Trust Company Limited(約11.12%)、FIL Limited(約10.24%)、FMR LLC(約10.04%)等。本公司並無控股股東。 |
|---|




